Poxel SA, a clinical-stage biopharmaceutical company, has agreed to sell its experimental kidney‑disease drug PXL770 to Scynexis Inc. in a deal worth up to $196 million. The transaction includes an $8 million upfront payment, with as much as $188 million tied to development and commercial milestones. PXL770 (set to be renamed SCY‑770) is a first‑in‑class activator of AMPK, a mechanism aimed at slowing cyst growth in autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cau...